Shares of Hims & Hers Health (NYSE:HIMS) rose about 7% following an announcement that the telehealth company expanded its prescribing capabilities to include select Eli Lilly weight-loss medications.
The company said that licensed providers using its platform can now transmit prescriptions for Zepbound vials and KwikPen, as well as Foundayo, to the LillyDirect pharmacy. The process includes access to self-pay pricing for Hims & Hers customers, and the functionality is intended to allow clinicians on the platform to help patients obtain FDA-approved GLP-1 medications.
This Eli Lilly expansion comes after Hims & Hers disclosed a partnership last month with Novo Nordisk to facilitate customer access to Wegovy injections and pills. The company characterized both moves as elements of a strategic shift in its U.S. weight-loss business, noting that they reflect a transformation in the market for FDA-approved GLP-1 treatments.
Hims & Hers described its weight-loss membership as including a suite of clinical and support services: 24/7 direct access to a care team, personalized nutrition guidance, regular clinical check-ins, and peer support through the Hims & Hers Weight Loss community. The company said its objective is to offer customers a variety of treatment choices together with an integrated care experience tailored to each individual’s medical history, preferences, needs, and goals.
Summary of the development
- Hims & Hers enabled prescriptions for specific Eli Lilly GLP-1 products to be routed to LillyDirect with self-pay pricing for its customers.
- The platform enhancement allows licensed providers to prescribe Zepbound vials, KwikPen, and Foundayo for patient access to FDA-approved GLP-1 therapy.
- The announcement followed a prior collaboration with Novo Nordisk to support access to Wegovy injections and pills.
Context included in the company release
- The company framed the actions as part of a strategic shift in its U.S. weight-loss business in response to changes in the GLP-1 treatment market.
- Hims & Hers emphasized a membership model that combines medication access with ongoing clinical and peer-support services.
Note on limits of the report
The information above reflects the company statements on platform capabilities, membership offerings, and positioning; it does not add details beyond those disclosures.